Publications and media
Gsundheit! 37. Baarer Heimatbuch 2019/2020
Cluster machen Unternehmen erfolgreicher - Pharma- und Medtech-Firmen in Baar
Read more...
arzt I spital I pflege, 23. September 2020
Erste Kinder in der Schweiz mit biologisch abbaubaren Herzimplantaten
Read more...
Cardiovascular News, August 2020, Issue 58
Carag Bioresorbable Septal Occluder approved for US IDE trial
Read more...
20 minutes, Lausanne & Genève 21.08.20
Première chirurgicale pour réparer un cœur
Read more...
20 Minuten, Regionalausgabe Zürich, 20.08.20
Weltneuheit: Kinder erhalten Herz-Implantat, das sich auflöst
Read more...
Kinderspital Zürich, Medienmitteilung, 19.08.20
Erfolgreich eingesetzt: Erste Kinder in der Schweiz mit biologisch abbaubaren Herzimplantaten
Read more...
Medtech Insight, August 6, 2020
Reed Miller: Carag Applies Bioabsorbable Material Technology To Transseptal Occluders
Read more...
Medical Device News Magazine, July 4, 2020
Carag Receives U.S. FDA IDE Approval for Its Carag Bioresorbable Septal Occluder
Read more...
BioWorld MedTech, July 2, 2020
Annette Boyle: Carag secures IDE approval for Bioresorbable Septal Occluder
Read more...
CardiacVascularNews, July 2, 2020
Carag Receives U.S. FDA IDE Approval to Conduct Clinical Study of First Transcatheter Septal Occluder With Bioresorbable, Metal-free Framework
Read more...
Cardiac Interventions Today, July 1, 2020
IDE Approved for Trial of Carag’s Transcatheter Bioresorbable Septal Occluder
Read more...
July 1, 2020
Carag receives U.S. FDA IDE approval to conduct clinical study of first transcatheter septal occluder with bioresorbable, metal-free framework
Read more...
CONTACT
CARAG AG Bahnhofstrasse 9 6340 Baar Switzerland
T +41 41 766 02 02 F +41 41 766 02 00 info@carag.com